Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731177 | 0.82 | MAPK8 (0.44) | ALDH1A1MAPK8MAPK9HPGDKDM4E | |
| SCHEMBL2730721 | 0.72 | RECQL (0.49) | ALDH1A1MAPK1HPGDKDM4EMEN1 | |
| SCHEMBL2730493 | 0.70 | MAPK8 (0.42) | ALDH1A1MAPK8MAPK9HPGDKDM4E | |
| SCHEMBL2730492 | 0.70 | MAPK8 (0.42) | ALDH1A1MAPK8MAPK9HPGDKDM4E | |
| SCHEMBL17199972 | 0.67 | MAPK8 (0.46) | ALDH1A1MAPK8MAPK9HPGDKDM4E | |
| SCHEMBL2731589 | 0.66 | FOLH1 (0.46) | ALDH1A1RORCKDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2732706 | 0.66 | MAPK8 (0.45) | ALDH1A1MAPK8MAPK9HPGDKDM4E | |
| SCHEMBL15452835 | 0.61 | MAPK8 (0.50) | ALDH1A1MAPK8MAPK9HPGDKDM4E | |
| SCHEMBL30462688 | 0.61 | KDM4E (0.59) | ALDH1A1MAPK1KDM4E | |
| SCHEMBL39208 | 0.61 | KDM4E (0.59) | ALDH1A1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | disclosed |
| EP-2635567-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2013-09-11 | — | — | EP | disclosed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | disclosed |
| WO-2012059776-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217702-A1 | INDOLE DERIVATIVES | BDKRB1, BDKRB2, ARRB1 | ALDH1A1 1752/4885MAPK8 2519/4885MAPK9 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.